| Literature DB >> 32103936 |
Chen-Guang Liu1,2, Ya-Hui Han1,2, Ranjith Kumar Kankala1,2,3, Shi-Bin Wang1,2,3, Ai-Zheng Chen1,2,3.
Abstract
With the advent of nanotechnology, various modes of traditional treatment strategies have been transformed extensively owing to the advantageous morphological, physiochemical, and functional attributes of nano-sized materials, which are of particular interest in diverse biomedical applications, such as diagnostics, sensing, imaging, and drug delivery. Despite their success in delivering therapeutic agents, several traditional nanocarriers often end up with deprived selectivity and undesired therapeutic outcome, which significantly limit their clinical applicability. Further advancements in terms of improved selectivity to exhibit desired therapeutic outcome toward ablating cancer cells have been predominantly made focusing on the precise entry of nanoparticles into tumor cells via targeting ligands, and subsequent delivery of therapeutic cargo in response to specific biological or external stimuli. However, there is enough room intracellularly, where diverse small-sized nanomaterials can accumulate and significantly exert potentially specific mechanisms of antitumor effects toward activation of precise cancer cell death pathways that can be explored. In this review, we aim to summarize the intracellular pathways of nanoparticles, highlighting the principles and state of their destructive effects in the subcellular structures as well as the current limitations of conventional therapeutic approaches. Next, we give an overview of subcellular performances and the fate of internalized nanoparticles under various organelle circumstances, particularly endosome or lysosome, mitochondria, nucleus, endoplasmic reticulum, and Golgi apparatus, by comprehensively emphasizing the unique mechanisms with a series of interesting reports. Moreover, intracellular transformation of the internalized nanoparticles, prominent outcome and potential affluence of these interdependent subcellular components in cancer therapy are emphasized. Finally, we conclude with perspectives with a focus on the contemporary challenges in their clinical applicability.Entities:
Keywords: cancer therapy; intracellular pathways; nanocomposites; organelle; proton sponge effect
Mesh:
Substances:
Year: 2020 PMID: 32103936 PMCID: PMC7008395 DOI: 10.2147/IJN.S226186
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1Schematic illustration showing the intracellular performance and fate of nanoparticles in cancer therapy that explicitly determining their internalization, interaction with different subcellular organelles, delivery of drugs, and mechanisms of action.
Abbreviation: ETC, electron transport chain.
Examples Presenting Different Organelle-Targeted Nanoformulations for Cancer Therapy
| Organelle | Composition | Size/nm | Responsiveness | Pathway | Outcome | Reference |
|---|---|---|---|---|---|---|
| Endosome/ | LDH-hydrazone-Dox | 104.33±14.15 | pH | Proton sponge effect | Enhanced ROS generation | [ |
| ORMOSIL NPs | <100 | Autophagy | Caveolae-mediated endocytosis | Endocytosis and subcellular localization | [ | |
| CALNN-capped gold nanoparticles | 5 | – | Peptide cleavage by the protease cathepsin L | Applied for Biosensing, fluorescence quenching | [ | |
| pRNA-3WJ | 5–20 | Immune | Internalized through endocytosis | Endosomal escape for siRNA delivery | [ | |
| FA-SLICS | – | pH | Internalized through the receptor-mediated endosomal pathway | Controlling the release of loaded genes by the endosomal microenvironment | [ | |
| L-histidine-based polymeric micelles | – | pH | Endosomolytic activity | Ablating drug-sensitive ovarian cancer as well as drug-resistant counterpart cells | [ | |
| V-ATPase inhibition | – | Cisplatin | ERK/MEK | Regulating autophagy that assisting in chemoresistance in ovarian cancer | [ | |
| YPSMA-1-PEOz-PLA | – | pH | Degradative lysosomes pathway | Efficient delivery of anticancer drugs for treating PSMA-positive prostate cancers | [ | |
| Nanosomes | – | Carbohydrate–lectin | LMP pathway | Facilitating targeted molecular delivery and intracellular traffic through an endocytic route without the influence of protein corona | [ | |
| T-UPSM | 37.6±1.9 | pH | Lysosomal catabolism inhibition | KRAS mutant pancreatic cancer treatment through simultaneous lysosomal pH buffering and rapid drug release | [ | |
| F-Gly-MTX NPs | 46.82±5.03 | Enzymatic, pH | Acid lysosomal compartment and protease | Release of the MTX via peptide bond cleavage in the presence of proteinase K | [ | |
| Mitochondria | CdTe QDs | 5.5 | – | Inhibition of mitochondrial respiration and induce mitochondrial MPT | Augmented cell apoptosis and demonstration of QDs toxicity at subcellular (mitochondrial) level | [ |
| TPP-CeO2 | 2.2 | – | Scavenge mitochondrial ROS efficiently to reduce oxidative stress | Suppression of neuronal death | [ | |
| PDA-PEG-TPP-DOX | 28 | pH | Enormous levels of ROS generation | Overcoming drug resistance in cells | [ | |
| TL-CPT-PEG1000-TPP with DSPE-PEG | 77.1~149.4 | ROS | Elevate PDT efficacy and interfering with DNA replication as a topoisomerase inhibitor | Augmented chemotherapy and PDT | [ | |
| AuNPs@CP/SA | 20 | – | Efficient dynamin-dependent and caveolae-mediated endocytosis pathway | Highly specific localization in mitochondria | [ | |
| Nucleus | DOX@MSN@TAT/RGD | 38.6~47.2 | – | Vasculature-/membrane-to-nucleus sequential drug-delivery strategy exploiting RGD and TAT dual-peptides | Enhanced in vivo chemotherapeutic efficacy in clinics | [ |
| IONPs-TAT/PEG | 20 | – | Enhancing the therapeutic effect by nuclear targeting | Simultaneous cancer targeting, imaging, and PTT | [ | |
| UCNPs@TiO2-Ce6-TAT | 25 | NIR light (980 nm) | Generation of multiple ROS (˙OH, O2−, and 1O2) using the dual-photosensitizer | Enhancing PDT can be achieved against MDR cancer | [ | |
| Chitosan nanoparticles-NLS | 25, 150 | – | Study on impaired nuclear import and aberrant nanoparticle intracellular trafficking in glioma | Effect of nanoparticle size and NLS density on nuclear targeting in cancer and normal cells | [ | |
| AuNPs@PEG@RGD/NLS | 35 | – | Mechanical stiffness of the nucleus and stimulate the overexpression of lamin A/C located around the nuclear membrane | Increasing nuclear stiffness and slowing cancer cell migration and invasion | [ | |
| NLS/RGD-AgNPs | 35 | – | ROS generation and effect on cell cycle and cell division | DNA damage and apoptosis | [ | |
| Acridin-9-Methanol nanoparticles | 60 | Visible light (≥410 nm) | Nucleus targeted intracellular controlled drug release | Fluorescent imagine and killing the cancer cells | [ | |
| Golgi apparatus | PTX–CS–RA | 192.7±1.8 | pH | Loss of cystic structure | Enhancement of antimetastasis combined with chemotherapy | [ |
| M-COPA | – | – | EGFR-TKIs | Overcoming the vicious cycle of TKI resistance in EGFR-mutated NSCLC cells via downregulating cell surface RTK expression | [ | |
| Alb-GNPs | 49 | – | Caspase-3 | PTT of Alb-conjugated GNPs in liver cancer-initiating Golgi apparatus-endoplasmic reticulum dysfunction with consequent caspase-3 apoptotic pathway activation and cellular apoptosis | [ | |
| ANQ-IMC-6 | – | Fluorophore | Cyclooxygenase-2 | Visualizing dynamic changes of the Golgi apparatus during cancer cell apoptosis and possible application in early diagnosis | [ | |
| Amicoumacin A | 0.31 | – | Translation elongation inhibition | Translation inhibition in yeast and mammalian systems by affecting the translation elongation | [ | |
| Ribosome | LUCAT1 lncRNA | – | – | L40-MDM2-p53 | Suppression of LUCAT1 inducing CRC cell cycle arrest and apoptosis by binding UBA52 and activating the RPL40-MDM2-p53 pathway | [ |
| Dd-mrp4 | – | – | p53- or RB-like functions | Ectopically expressed Dd-mrp4 suppressing the cell proliferation through inducing apoptotic cell death | [ |
Abbreviations: Alb-GNPs, Albumin-gold nanoparticles; AgNPs, Silver nanoparticles; ANQ-IMC-6, Acenaphtho[1,2-b]quinoxaline-indomethacin-6; AuNPs@CP/SA, Gold nanoparticles coated by biotin-NNLACCALNN-COOH/tetrameric streptavidin molecules; CdTe QDs, Cadmium telluride quantum dots; Dd-mrp4, Dictyostelium mitochondrial ribosomal protein S4; DSPE-PEG, 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)]; EGFR-TKIs, Epidermal growth factor receptor-tyrosine kinase inhibitors; FA-SLICS, Folic acid functionalized Schiff-base linked imidazole chitosan; F-Gly-MTX NPs, Methotrexate-conjugated glycine-coated magnetic nanoparticles; PDA, Polydopamine; IONP-TAT, Iron oxide nanoparticles-YGRKKRRQRRR peptide; LDHs, Layered double hydroxides; M-COPA, 2-methylcoprophilinamide; MDR, Multidrug resistance; MSN, Mesoporous silica nanoparticles; NLS, Nuclear localization sequence; ORMOSIL NPs, Organically-modified silica nanoparticles; PDT, Photodynamic therapy; pRNA-3WJ, Three-way junction motif of packaging RNA molecules; PTT, Photothermal therapy; PTX-CS-RA, Retinoic acid-conjugated chondroitin sulfate loading with paclitaxel; RGD, RGDRGDRGDRGDPGC peptide; RTK, receptor tyrosine kinases; TAT, a HIV peptide; TL-CPT, thioketal linker-modified camptothecin; TPP, triphenylphosphonium; T-UPSM, Triptolide prodrug-loaded ultra-pH-sensitive micelles; UCNPs@TiO2-Ce6-TAT, NaFY4:Yb,Er,Tm@TiO2-Chlorin e6-TAT; YPSMA-1-PEOz-PLA, Anti-(prostate specific membrane antigen) antibody-poly(2-ethyl-2-oxazoline)-poly(D, L-lactide).
Figure 2Proposed interactions between peptides (rectangles) and lipid bilayers. (A) Peptides are soluble in water but have a high affinity for binding to lipid bilayers. (B) Peptides inserting into the head group region stretch the membrane area, cause thinning of the chain region, and thus create an internal membrane tension. (C) Peptides preferentially bind to the edges of the pores, which have the consequence of loosening the internal membrane tension. (The depicted pores are called toroidal, or wormhole models. Some peptides make barrel-stave pores. It should be noted that the mechanism is the same for both types of pores.) Reprinted figure with permission from Huey W Huang, Fang-Yu Chen, and Ming-Tao Lee, Physical Review Letters, 92(19), 2004.] Copyright 2004 by the American Physical Society.106
Figure 3Schematic illustrating the proton sponge effect leading to the lysosomal damage and the induction of cytotoxicity by the cationic nanoparticles. Cationic (for example, PEI-coated) nanoparticles bind with high affinity to lipid groups on the surface membrane and are endocytosed in the tight-fitting vesicles. Reprinted by permission from Springer Nature, Nature Materials, Understanding biophysicochemical interactions at the nano-bio interface, Nel AE, Madler L, Velegol D, et al., Copyright 2009.55
Figure 4The EGFP-Rab7 wt fusion protein is mainly associated with lysosomes. Green corresponds to the EGFP signal (A, D and G) and red to the immune-detected markers CI-MPR (B), Lamp-1 (E), and cathepsin D (H). (C), (F), and (I) show the merged images, where yellow indicates co-localization. Note that the co-localization of EGFP-Rab7 wt with CI-MPR is only partial (C), whereas there is a more distinct co-localization of EGFP-Rab7 wt with Lamp-1 (F) and cathepsin D (I). Bars, 20 mm. (J, K and L) Immuno-gold labeling of cells expressing the EGFP-Rab7 wt. The panels show examples of large vesicular structures forming tightly packed aggregates. These structures appear as multi-vesicular bodies with numerous small, internal vesicles, or they have a more typical lysosome appearance with a dense content of membranous material. Note that all of these aggregated, late endosome/lysosome–like structures (Ly) are distinctly labeled for EGFP (10-nm gold; arrowheads) on the cytoplasmic surface of their outer membranes, as well as for Lamp-1 internally (15-nm gold, small arrows). Correspondingly, note that minimal cytosolic labeling for EGFP is seen. Bar, 250 nm. Republished with permission of American Society for Cell Biology, Rab7: a key to lysosome biogenesis, Bucci C, Thomsen P, Nicoziani P, Mccarthy J, Bo VD, 11(2), 2000; permission conveyed through Copyright Clearance Center, Inc.108
Figure 5(A) Lysosome-aimed strategy for simultaneously targeted delivery, lysosomal imaging and destruction, and real-time self-feedback of therapeutic efficacy. Real-time monitoring of fluorescence and morphology during PDT. (B) a–h) Real-time fluorescence images at λEx/Em of 633/660–720 nm (top) and bright-field images (bottom) of Apt-TNP-loaded MDA-MB-231 cells under 808 nm irradiation at 100 mW cm−2. i) Merged fluorescence and bright field image at the starting time of PDT. Scale bar, 20 mm. j) Time course of fluorescence intensity collected at dots 1–4 shown in (i), corresponding to the lysosomes (1, 3) and cytosol (2, 4). Tian J, Ding L, Ju H, et al. A multifunctional nanomicelle for real-time targeted imaging and precise near-infrared cancer therapy. Angew Chem Int Ed. 2014;53(36):9544–9549. With permission from Copyright 2014 John Wiley and Sons.63
Figure 6Schematic illustrating the p53 accumulation in the mitochondrial matrix and triggering the opening of mtPTP and substantial necrosis by the physical interaction with the PTP regulator Cyp-D. Reprinted from Cell, 149(7), Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM, p53 opens the mitochondrial permeability transition pore to trigger necrosis, 1536–1548, Copyright 2012, with permission from Elsevier.145
Figure 7(A, B) Illustration of pH-PTT as a smart drug system for specific Golgi apparatus-activated PTT. (C) BSA-pH-PTT/Mito tracker (c and d) and BSA-pH-PTT/Golgi green. (1) Red channel: 650 ± 25 nm for BSA-pH-PTT (25 mM), λex = 543 nm; (2) green channel: 530 ± 25 nm for Lysotracker (200 nM), Mito tracker (500 nM) or Golgi tracker (200 nM), λex = 488 nm; (3) merged images; (4) bright field and (5) enlarged images of 3, scale bar: 50 mm. Reproduced with permission of Royal Society of Chemistry from A smart drug: a pH-responsive photothermal ablation agent for Golgi apparatus activated cancer therapy, Xue F, Wen Y, Wei P, et al., 2017.25